NASDAQ:VTYX Ventyx Biosciences (VTYX) Stock Price, News & Analysis $2.40 -0.05 (-2.04%) Closing price 04:00 PM EasternExtended Trading$2.40 +0.00 (+0.21%) As of 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ventyx Biosciences Stock (NASDAQ:VTYX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ventyx Biosciences alerts:Sign Up Key Stats Today's Range$2.31▼$2.4550-Day Range$2.02▼$3.2752-Week Range$0.78▼$3.39Volume479,394 shsAverage Volume622,795 shsMarket Capitalization$171.14 millionP/E RatioN/ADividend YieldN/APrice Target$7.50Consensus RatingModerate Buy Company Overview Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California. Read More Ventyx Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreVTYX MarketRank™: Ventyx Biosciences scored higher than 51% of companies evaluated by MarketBeat, and ranked 547th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingVentyx Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVentyx Biosciences has received no research coverage in the past 90 days.Read more about Ventyx Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Ventyx Biosciences are expected to decrease in the coming year, from ($2.09) to ($2.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ventyx Biosciences is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ventyx Biosciences is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVentyx Biosciences has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Ventyx Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.52% of the float of Ventyx Biosciences has been sold short.Short Interest Ratio / Days to CoverVentyx Biosciences has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ventyx Biosciences has recently decreased by 4.43%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVentyx Biosciences does not currently pay a dividend.Dividend GrowthVentyx Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.52% of the float of Ventyx Biosciences has been sold short.Short Interest Ratio / Days to CoverVentyx Biosciences has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ventyx Biosciences has recently decreased by 4.43%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.47 News SentimentVentyx Biosciences has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Ventyx Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for VTYX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Ventyx Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ventyx Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders14.49% of the stock of Ventyx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.88% of the stock of Ventyx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ventyx Biosciences' insider trading history. Receive VTYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VTYX Stock News HeadlinesVentyx Biosciences to Participate in Three Upcoming Investor ConferencesAugust 27 at 7:02 AM | globenewswire.comPiper Sandler Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)August 23, 2025 | theglobeandmail.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 29 at 2:00 AM | The Oxford Club (Ad)H.C. Wainwright Keeps Their Hold Rating on Ventyx Biosciences (VTYX)August 23, 2025 | theglobeandmail.comVentyx Biosciences Reports Decreased Losses in 2025August 15, 2025 | msn.com3 Best Stocks to Buy Now, 8/11/2025, According to Top AnalystsAugust 11, 2025 | msn.comVentyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate ProgressAugust 9, 2025 | finance.yahoo.comVentyx (VTYX) Q2 Net Loss Drops 16%August 9, 2025 | theglobeandmail.comSee More Headlines VTYX Stock Analysis - Frequently Asked Questions How have VTYX shares performed this year? Ventyx Biosciences' stock was trading at $2.19 at the start of the year. Since then, VTYX stock has increased by 9.6% and is now trading at $2.40. How were Ventyx Biosciences' earnings last quarter? Ventyx Biosciences, Inc. (NASDAQ:VTYX) released its quarterly earnings data on Thursday, August, 7th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.07. When did Ventyx Biosciences IPO? Ventyx Biosciences (VTYX) raised $152 million in an initial public offering on Thursday, October 21st 2021. The company issued 9,472,656 shares at a price of $15.00-$17.00 per share. Who are Ventyx Biosciences' major shareholders? Top institutional shareholders of Ventyx Biosciences include Affinity Asset Advisors LLC (6.36%), Marshall Wace LLP (3.36%), Sio Capital Management LLC (1.83%) and Redmile Group LLC (1.56%). Insiders that own company stock include Somu Subramaniam, Nsv Partners Iii Lp, Raju Mohan, John Nuss, Christopher W Krueger, Sheila Gujrathi, William J Sandborn and Martin Auster. View institutional ownership trends. How do I buy shares of Ventyx Biosciences? Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ventyx Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ventyx Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings8/07/2025Today8/29/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VTYX CIK1851194 Webwww.ventyxbio.com Phone760-593-4832FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Ventyx Biosciences$7.50 High Price Target$9.00 Low Price Target$6.00 Potential Upside/Downside+221.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$135.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-48.89% Return on Assets-44.87% Debt Debt-to-Equity RatioN/A Current Ratio19.12 Quick Ratio19.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.94 per share Price / Book0.79Miscellaneous Outstanding Shares71,310,000Free Float60,976,000Market Cap$166.51 million OptionableOptionable Beta0.97 Social Links The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:VTYX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.